|
|
|
The IMF is making news all year round.
|
|
|
|
|
|
The FDA Has Granted Marketing Authority for Mozobil with Granulocyte-Colony Stimulating Factor in Patients with Multiple Myeloma and Non-Hodgkin’s Lymphoma |
|
|
|
|
Treatment Progress Takes on New Urgency as Incidence of Myeloma Continues to Rise |
|
|
|
|
Will Study Circulating DNA as a Marker for and Potential Cause of Disease Recurrence |
|
|
|
|
"We support efforts that put patients first… and work for better outcomes until there is a cure," Susie Novis, IMF President |
|
|
|
|
Renowned French Scientist Instrumental in Studying the Role of Viruses in Multiple Myeloma |
|
|
|
The Wellsphere Health Impact Award honors individuals and organizations making the greatest impact in the lives of patients. |
|
|
|
|
With these new approvals, patients with multiple myeloma may now receive VELCADE earlier following an initial disease diagnosis. |
|
|
|
|
The Prix Galien Award recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines. |
|
|
|
|
Writing in the October 10th edition of the Journal of Clinical Oncology, IMF chairman Brian G.M. Durie, M.D., notes that 25 years ago only 48 percent to 66 percent of myeloma patients survived two years, depending on which treatment was used. By contrast today, two-year survival rates are around 90 percent. |
|
|
|
|
New Indication Provides Treatment-Free Interval As an Option |
|
|
|
|
Encouraging new findings were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, showing significant improvements in treating myeloma. |
|
|
|
|
Consensus Statements Will Be Published in the Clinical Journal of Oncology Nursing and Will Be Presented in Conjunction with the Oncology Nursing Society Annual Meeting May 16th |
|
|
|
|
The European Commission Grants Marketing Authority for Melphalan-Prednisone-Thalidomide Regimen |
|
|
|
Founded the Italian Myeloma Study Group, a Pioneering Investigator Consortium in Europe |
|
|
|
|
Priority review puts VELCADE on track for potential approval in mid-2008 |
|
|
|
|
Positive Opinion from EU Advisory Committee Could Mark the Return of Thalidomide to Europe |
|
|
|
|
BiRD Study (Biaxin®-Revlimid-Dexamethasone) Provides Evidence of Deep Complete Response Rates In Newly Diagnosed Multiple Myeloma |
|
|
|
|
BANK ON A CURE® DNA Data Base also finds Genetic Link to Bone Disease and Indications for Treatment |
|
|
|
|
Survival and Longer Term Disease Control Take Precedence over Short Term Response to Treatment |
|
|
|
|
Findings to be presented at ASH show that even without a cure there are dramatic improvements in treatment and survival for patients with myeloma. |
|
|
|
|
Two Studies in the Prestigious New England Journal of Medicine Validate the Findings. |
|
|
|
|
Findings Could Support Marketing Authorization for thalidomide in Europe |
|
|
|
|
The combination therapy of VELCADE, melphalan and prednisone (VMP) demonstrates a significant advantage for patients newly diagnosed with myeloma. The therapy is already approved for use in patients who have received a previous treatment. |
|
|
|
|
For firefighters safety doesn’t end when the fire is over. Studies have shown firefighters are at higher risk for myeloma, and the risk increases with length of service. Most recently, studies linked an increased risk of myeloma to exposures at the World Trade Center site following 9/11. |
|
|
|
|
NLB Poster at the International Myeloma Workshop Represents a Major Advance in Nursing Care. (Article includes PDF of poster.) |
|
|
|
|
"Today we have multiple options for treatment, and for many patients survival is being measured in years, not months, with an excellent quality of life," says Susie Novis. |
|
|
|
|
With today's action REVLIMID is now approved in Europe for myeloma patients who have received at least one prior therapy. |
|
|
|
|
Data Presented at the ASCO Cancer Conference |
|
|
|
|
In an article entitled "The Legacy of the World Trade Center Dust," physicians say more than 5 years after the World Trade Center disaster, "uncertainty and controversy remain about the health risks posed by inhaling dust, the subsequent fires and the cleanup effort." |
|
|
|
|
Combination Provides 43% Improvement in Time to Disease Progression |
|
|
|
|
Second Closure of Multi-Center Trial in 4 Weeks Reinforces Benefits of Using REVLIMID® with Low Dose Steroids in Myeloma |
|
|
|
|
New Program Developed Following Meetings to Address Patient Questions and Concerns |
|
|
|
|
Findings Show Survival Improvement with Lower Doses of Dexamethasone, the Steroid Commonly Used with REVLIMID® and other Drugs in Newly Diagnosed Myeloma
|
|
|
|
|
Patients, Advocates and Experts Applaud Positive Opinion from EU Advisory Committee |
|
|
|
|
The International Myeloma Foundation (IMF) today announced the appointment of Heather Cooper Ortner as vice president of development. Heather comes to the IMF from the Brandeis-Bardin Institute where she was director of development for the past three years. Her appointment is effective immediately.
|
|
|
|
|
The survey also found that the IMF excels in areas that matter most to patients: being extremely knowledgeable about issues related to myeloma, having up-to-date information, and putting the needs of patients and caregivers as the first priority. |
|
|
|
|
"Blood cancers, including myeloma, are the third most common form of cancer, and today new therapies are transforming the way we treat them," said Susie Novis, president and co-founder of the International Myeloma Foundation. "While the benefits from most cancer treatment are measured in months, we are seeing many of our patients experience long-term responses measured in years with new I.V. and oral medications." |
|
|
|
Michael Tuohy, a 7-year Cancer Survivor, Diagnosed When He Was Just 36, Will Travel with His Wife and Children. Communities Who Would Like a Visit May Contact the IMF. |
|
|
|
|
Findings Explain Why Certain Patients Suffer Blood Clots from Thalidomide; and Why Aspirin Works as an Intervention |
|
|
|
|
Collectively, these studies represent a significant increase in knowledge of how myeloma responds to treatment, which is already becoming applicable to other cancers. |
|
|
|
Nursing Leadership Board Will Provide Education, Updates and Reviews of Medical Protocols and Trends in Supportive Care. |
|
|
|
|
The International Myeloma Foundation -- a not-for-profit organization supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians -- is bringing leading experts to the Doubletree Hotel, August 4th and 5th, to discuss the latest trends and developments changing the face of cancer care. These new developments include the recent approval of the once controversial drug thalidomide for multiple myeloma, the anticipated approval this month of a related drug called Revlimid, and new survival data, just released at a scientific conference. |
|
|
|
The findings,presented at the 47th Annual Meeting of the American Society of Hematology (ASH), identify individual genetic differences that may be associated with risk factors for developing myeloma and with adverse reactions to therapies in patients who have myeloma. |
|
|
|
|
A new study published today on-line on the Journal of Clinical Oncology’s web site demonstrates the effectiveness of a new staging system for multiple myeloma, a cancer of the plasma cells in the bone marrow. The new International Staging System (ISS) provides a simple prognostic factor alternative to the Durie and Salmon clinical staging system used for more than 25 years. The collaborative efforts of the IMF International Myeloma Working Group led to the development the ISS after more than four years |
|
|
|
The IMF will be reporting highlights of the prestigious 10th International Myeloma Workshop, the premiere meeting regarding multiple myeloma. The Workshop is being held April 10-14 in Sydney, Australia. |
|
|
|
|
The IMF is proud to have received a four-star rating of “Exceptional” from Charity Navigator. The four-star rating, the highest rating available from the organization, indicates that the IMF “exceeds industry standards and outperforms most charities in its Cause.” |
|
|
|
Celgene Corporation reported that Revlimid, also known as lenalidomide, has shown outstanding results in the treatment of relapsed or refractory myeloma in two Phase III clinical trials. |
|
|
|
“The IMF is extremely pleased that Medicare has expanded coverage for PET scans for myeloma patients in certain circumstances,” said Brian Durie, M.D., IMF Chairman. “We have worked hard for reimbursement because we believe PET scanning is an important tool for diagnostic evaluation, staging, and monitoring for myeloma. This is a very encouraging decision by Medicare, and an important step forward for myeloma patients.” |
|
|
|
Dr. Anderson is being honored for pioneering critical advances against multiple myeloma, leading not only to improved treatments, but also to a deeper understanding of how myeloma occurs at the basic level of cells and genes. |
|
|
|
|
CDC Recognizes Excellence of Current IMF Programs, Funds Expansion of Existing Programs |
|
|
|
|
The IMF believes that raising awareness in the medical professions about multiple myeloma is a critical step toward early diagnosis and encouraging the development of new treatments. |
|
|
|
|
Phase III (E1 A00) Study Results Presented at ASCO |
|
|
|
|
Program Recognizes Geraldine Ferraro’s Contributions |
|
|
|
|
Cancer Research Pioneer is Lifetime Achievement Award Recipient |
|
print
back to top